Arcturus Therapeutics (ARCT) vs Atea Pharmaceuticals (AVIR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Atea Pharmaceuticals (AVIR) has outperformed Arcturus Therapeutics (ARCT) over the past year, gaining 68.7% versus a loss of 37.6%. Over five years, ARCT leads with a -72.0% price change compared with -87.2% for AVIR. Atea Pharmaceuticals is the larger company by market cap ($418.7 million vs $364.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARCT | AVIR |
|---|---|---|
| Share price | $12.83 | $5.22 |
| Market cap | $364.67M | $418.67M |
| 1-day change | +0.51% | +4.19% |
| YTD return | +108.24% | +40.34% |
| 1-year return | -37.64% | +68.69% |
| 5-year return | -71.98% | -87.25% |
| EPS (TTM) | $-3.33 | $-2.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $24.17 | $6.45 |
| 52-week low | $5.50 | $2.87 |
| Distance from 52-week high | -46.92% | -19.07% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +80.83% | +80.46% |
| Average volume | 938.55K | 298.38K |
| Shares outstanding | 28.42M | 80.20M |
| Employees | 106 | 55 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AVIR has outperformed ARCT by 106.3 percentage points over the past year.
About Arcturus Therapeutics
ARCT stock →Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
About Atea Pharmaceuticals
AVIR stock →Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
ARCT vs AVIR FAQ
Which is bigger, Arcturus Therapeutics or Atea Pharmaceuticals?
Atea Pharmaceuticals (AVIR) is larger, with a market capitalization of $418.67M compared with $364.67M for Arcturus Therapeutics (ARCT).
Which stock has performed better over the past year, ARCT or AVIR?
AVIR returned +68.69% over the past 12 months, compared with -37.64% for ARCT (price return, excluding dividends). Past performance does not predict future results.
Are Arcturus Therapeutics and Atea Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.